Skip to main content
NCBI home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1998 Feb;51(1):26–29. doi: 10.1136/mp.51.1.26

Expression of mdm2 and p53 in epithelial neoplasms of the colorectum.

X P Hao 1, T Günther 1, A Roessner 1, A B Price 1, I C Talbot 1
PMCID: PMC395604  PMID: 9624416

Abstract

AIMS: To evaluate the respective roles of mdm2 (murine double minute 2) and p53 in the development of colorectal carcinoma. METHODS: Formalin fixed, paraffin wax embedded tissues from 72 sporadic adenomas and 55 carcinomas were investigated by means of immunohistochemistry for mdm2 and p53. RESULTS: mdm2 was expressed weakly in 17 of 72 (23.6%) adenomas and in 14 of 55 (25.4%) carcinomas. p53 was expressed in 19 of 72 (26.4%) adenomas and in 23 of 55 (41.8%) carcinomas. Four adenomas and five carcinomas showed positive staining for both proteins. Overexpression of p53 in adenomas was associated with moderate and severe dysplasia but not with tumour size. No associations were found between the expression of mdm2 and either the degree of dysplasia or tumour size. In carcinomas, neither the expression of p53 nor mdm2 correlated with Dukes's stage, metastasis, or differentiation. No associations were found between the expression of p53 and mdm2 in either adenomas or carcinomas. CONCLUSIONS: Although mdm2 has been reported to be an oncogene, it does not appear to play a major role in the development of colorectal carcinoma.

Full Text

The Full Text of this article is available as a PDF (200.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cahilly-Snyder L., Yang-Feng T., Francke U., George D. L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet. 1987 May;13(3):235–244. doi: 10.1007/BF01535205. [DOI] [PubMed] [Google Scholar]
  2. Chen J., Wu X., Lin J., Levine A. J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol. 1996 May;16(5):2445–2452. doi: 10.1128/mcb.16.5.2445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M. R., Pollack D., Woodruff J. M., Marechal V., Chen J., Brennan M. F., Levine A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994 Feb 1;54(3):794–799. [PubMed] [Google Scholar]
  4. Fakharzadeh S. S., Trusko S. P., George D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991 Jun;10(6):1565–1569. doi: 10.1002/j.1460-2075.1991.tb07676.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  6. Gorgoulis V. G., Zoumpourlis V., Rassidakis G. Z., Karameris A., Rassidakis A. N., Spandidos D. A., Kittas C. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol. 1996 Oct;180(2):129–137. doi: 10.1002/(SICI)1096-9896(199610)180:2<129::AID-PATH646>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  7. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997 May 15;387(6630):296–299. doi: 10.1038/387296a0. [DOI] [PubMed] [Google Scholar]
  8. Jones S. N., Roe A. E., Donehower L. A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995 Nov 9;378(6553):206–208. doi: 10.1038/378206a0. [DOI] [PubMed] [Google Scholar]
  9. Kessis T. D., Slebos R. J., Han S. M., Shah K., Bosch X. F., Muñoz N., Hedrick L., Cho K. R. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol. 1993 Nov;143(5):1398–1405. [PMC free article] [PubMed] [Google Scholar]
  10. Kubbutat M. H., Jones S. N., Vousden K. H. Regulation of p53 stability by Mdm2. Nature. 1997 May 15;387(6630):299–303. doi: 10.1038/387299a0. [DOI] [PubMed] [Google Scholar]
  11. Ladanyi M., Cha C., Lewis R., Jhanwar S. C., Huvos A. G., Healey J. H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 1993 Jan 1;53(1):16–18. [PubMed] [Google Scholar]
  12. Martin K., Trouche D., Hagemeier C., Sørensen T. S., La Thangue N. B., Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. 1995 Jun 22;375(6533):691–694. doi: 10.1038/375691a0. [DOI] [PubMed] [Google Scholar]
  13. Martinez J. C., Mateo M., Sánchez-Beato M., Villuendas R., Orradre J. L., Algara P., Sánchez-Verde L., García P., López C., Martínez P. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J Pathol. 1995 Sep;177(1):27–34. doi: 10.1002/path.1711770106. [DOI] [PubMed] [Google Scholar]
  14. Momand J., Zambetti G. P. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene. 1996 Jun 6;12(11):2279–2289. [PubMed] [Google Scholar]
  15. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992 Jun 26;69(7):1237–1245. doi: 10.1016/0092-8674(92)90644-r. [DOI] [PubMed] [Google Scholar]
  16. Montes de Oca Luna R., Wagner D. S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995 Nov 9;378(6553):203–206. doi: 10.1038/378203a0. [DOI] [PubMed] [Google Scholar]
  17. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992 Jul 2;358(6381):80–83. doi: 10.1038/358080a0. [DOI] [PubMed] [Google Scholar]
  18. Olson D. C., Marechal V., Momand J., Chen J., Romocki C., Levine A. J. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene. 1993 Sep;8(9):2353–2360. [PubMed] [Google Scholar]
  19. Pignatelli M., Stamp G. W., Kafiri G., Lane D., Bodmer W. F. Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer. 1992 Mar 12;50(5):683–688. doi: 10.1002/ijc.2910500503. [DOI] [PubMed] [Google Scholar]
  20. Reifenberger G., Liu L., Ichimura K., Schmidt E. E., Collins V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993 Jun 15;53(12):2736–2739. [PubMed] [Google Scholar]
  21. Sinicrope F. A., Ruan S. B., Cleary K. R., Stephens L. C., Lee J. J., Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995 Jan 15;55(2):237–241. [PubMed] [Google Scholar]
  22. Watanabe T., Hotta T., Ichikawa A., Kinoshita T., Nagai H., Uchida T., Murate T., Saito H. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood. 1994 Nov 1;84(9):3158–3165. [PubMed] [Google Scholar]
  23. Xiao Z. X., Chen J., Levine A. J., Modjtahedi N., Xing J., Sellers W. R., Livingston D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 1995 Jun 22;375(6533):694–698. doi: 10.1038/375694a0. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES